To present some of the ethical concerns pertaining to the anticipated use of apolipoprotein E genotyping in selecting therapy in Alzheimer's disease.
Method:
We review studies that support the utility of apolipoprotein E (APO E) genotyping for predicting drug responsiveness along with the published consensus statements and position papers related to APO E genotyping. Ethical issues pertaining to the use of APO E genotyping for pharmacogenetic purposes have not yet been fully explored, and these are discussed.
Results:
This paper explores the bioethics surrounding the use of APO E genotyping for pharmacogenetic purposes. The rapidly increasing pace of clinical trials in Alheimer's disease necessitates a critical examination of the evolving ethical issues. A framework for establishing guidelines is suggested.
Conclusions:
Clinical research trials for Alzheimer's disease with a genotyping component will increasingly be influenced by and benefit from a serious analysis of the ethics emerging alongside the scientific and clinical advances.
Canadian Study of Health and Aging Workgroup. Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J1994;150:899–913.
2.
KatzmanRKawasC. The epidemiology of dementia and Alzheimer's disease. In: TerryRDKatzmanRBickKL, editors. Alzheimer's disease. New York: Raven Press; 1994. p 105–22.
3.
BachmanDLWolfPALinnRKnoefelJECobbJL, Belanger AJ, and others. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham study. Neurology1993;43:515–9.
4.
AlloulKSauriolLKennedyWLaurierCTessierG, Novosel S, and others. Alzheimer's disease: A review of the disease, its epidemiology and economic impact. Archives of Gerontolgy and Geriatrics1998;27:189–221.
5.
BrodatyHConneallyMGauthierSJenningsCLennoxA, Lovestone S, and others. Consensus statement on predictive testing for Alzheimer's disease. Alzheimer Dis Assoc Disord1995;9:182–7.
6.
Consensus statement of the American College of Medical Genetics/American Society of Human Genetics Working Group on APOE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA1995;274:1627–9.
7.
Consensus statement of the National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet1996;347:1091–5.
8.
PostSGWhitehousePJBinstockRHBirdTDEckertSK, Farrer LA, and others. Consensus statement: The clinical introduction of genetic testing for Alzheimer disease. JAMA1997;277:832–40.
9.
RosesAD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol1995;38:6–14.
10.
NebertDWWeberWW. Pharmacogenetics. In: PrattWBTaylorP, editors. Principles of drug action: The basis of pharmacology. 3rd ed.New York: Churchill Livingston; 1990. p 469–531.
11.
WestWLKnightEMPradhenSHindsTS. Interpatient variability: Genetic predisposition and other genetic factors. J Clin Pharmacol1997;37:635–48.
12.
GiacobiniE. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int1998;32:413–9.
13.
CorderEHSaundersAMStrittmatterWJSchmechelDEGaskellPC, Small GW, and others. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993;261:921–3.
14.
MaestreGOttmanRSternYGurlandBChunM, Tang MX, and others. Apolipoprotein E and Alzheimer's disease: Ethnic variation in genotypic risks. Ann Neurol1995;37:254–9.
15.
MayeuxRSternYOttomanRTatemichiTKTangMX, Maestre G, and others. The apolipoprotein ε4 allele in patients with Alzheimer's disease. Ann Neurol1993;34:752–4.
16.
SaundersAMStrittmatterWJSchmechelDGeorge-HyslopPHSPericak-VanceMA, Joo SH, and others. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology1993;43:1467–72.
17.
Van DuijnCMde KnijffPCrutsM. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet1994;7:74–8.
18.
PoirierJDavignonJBouothillierDKoganSBertrandPGauthierS. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet1993;342:697–9.
19.
HendersonASEastealSJormAFMackinnonAJKortenAE, Christensen H, and others. Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet1995;346:1387–90.
20.
PolvikoskiTSulkavaRHaltiaMKainulainenKVuorioA, Verkkoniemi A, and others. Apolipoprotein E. dementia, and cortical deposition of -amyloid protein. N Engl J Med1995;333:1242–7.
21.
SoininenHKosunenOHelisalmiSMannermanA, Paljarvil, Talasniemi S, and others. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein E4 allele. Neurosci Lett1995;187:79–82.
22.
PoirierJDelisleM-CQuirionRAubertIFarlowM, Lahiri D, and others. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA1995;92:12260–4.
23.
PoirierJ. Neurobiology of apolipoprotein E in the normal brain and in Alzheimer's disease. In: IqbalKWinbladBNishimuraTTakedaMWisniewskiHM, editors. Alzheimer's disease: Biology, diagnosis and therapeutics. New York: John Wiley & Sons; 1997. p 93–101.
24.
RichardFHelbecqueNNeumanEGuezDLevyRAmouyelP. APOE genotyping and response to drug treatment in Alzheimer's disease.[Letter]Lancet1997;349:539.
25.
FarlowMRLahiriDKPoirierJDavignonJHuiS. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci1996;802:101–10.
26.
FarlowMRLahiriDKPoirierJDavignonJSchneiderLHuiSL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology1998;50:669–77.
27.
PoirierJ. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psyhiatry Neurosci1999;24:147–53.
28.
SiestGPillotTRegis-BaillyALeiningermullerBSteinmetzJ, Galteau PM, and others. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem1995;41:1068–86.
29.
WilsonPWFMyersRHLarsonMGOrdovasJMWolfPASchaeferEJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham offspring study. JAMA1994;272:1666–71.
30.
RosesADBryanJBryanK. Apolipoprotein E genotype: Utility in clinical practice in Alzheimer's disease. J Am Geriatr Soc1996;44:1479–81.
31.
RosesAD. Alzheimer's disease: The genetics of risk. Hosp Pract1998;32:51–68.
32.
JarvikGPWijsmanEM. Alzheimer's disease and the family effect. [Letter]. Nat Genet1994;8:115.
33.
JarvikGP. Genetic predictors of common disease: Apolipoprotein E genotype as a paradigm. Ann Epidemiol1997;7:357–62.
34.
KeyserlingkEWGlassKKoganSGauthierS. Proposed guidelines for the participation of persons with dementia as research subjects. Perspect Biol Med1995;38:319–62.
35.
GlassKCSomervilleMA. Informed consent to medical research on persons with Alzheimer's disease: Ethical and legal parameters. In: BergJMKarlinskyHLowyFH, editors. Alzheimer's disease research: Ethical and legal issues. Toronto: Carswell; 1991. p 30–59.
36.
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. A report by a working group of the three federal funding councils: Medical Research Council of Canada. Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada; 1998.
37.
National Bioethics Advisory Commission. Research involving persons with mental disorders that may affect decisionmaking capacity: Report and recommendations of the National Bioethics Advisory Commission. Volume I. Rockville (MD): National Bioethics Advisory Commission; 1998.
38.
GauthierSPanissetMNalbantogluJPoirierJ. Alzheimer's disease: Current knowledge, management and research. Can Med Assoc J1997;157:1047–52.
39.
GhikaJ. Toward a treatment for dementia. Schweizerische Rundschau fur Medizin Praxis1995;84:1050–3.
40.
Mendes-OliveiraJRFilhoLima JLShimokomakiCMOkumaMPassosbuenoMR, Zatz M, and others. The use of apolipoprotein E genotype for preclinical detection of risk's group for Alzheimer's disease. Am J Med Genet1997;74:216–7.
41.
Code of Federal Regulations 45 CFR 46.404–46.406.
42.
SherringtonRRogaevEILiangYRogaevaEALevesqueG, Ikeda M, and others. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature1995;375:754–60.
43.
WraggMHuttonMTalbotC. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet1996;347:509–12.
44.
Pericak-VanceMABassMPYamaokaLHGaskellPCScottWK, Terwedow HA, and others. Complete genomic screen in late-onset familial Alzheimer disease: Evidence for a new locus on chromosome 12. JAMA1997;278:1237–41.
45.
RogaevaEPremkumarSSongYSorbiSBrindleN, Paterson A, and others. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA1998;280:614–8.
46.
KnoppersBM. Towards a reconstruction of the “genetic family”: New principles?International Digest of Health Legislation, 1998;49:241–53.
47.
BirdTD. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: A cautionary view. Ann Neurol1995;38:2–4.
48.
RosesAD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiology of Disease, 1997;4:170–86.
49.
TangMXMaestreGTsaiWYLuiXHFengL, Chung WY, and others. Relative risk of Alzheimer's disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet1996;58:574–84.
50.
TangMXSternYMarderKBellKGurlandB, Lantiqua R, and others. The APOE – epsilon 4 allele and the risk of Alzheimer's disease among African Americans, Whites, and Hispanics. JAMA1998;279:751–5.
51.
WangWO. Cultural competency in genetic counseling. Journal of Genetic Counsel1994;3:267–77.
52.
Punales-MorejonDRappR. Ethnocultural diversity and genetic counseling training: The challenge for a twenty-first century. Journal of Genetic Cousel1993;2:155–8.
53.
WeilJMittmanI. A teaching framework for cross-cultural genetic counseling. Journal of Genetic Counsel1993;2:159–69.
54.
GuintaSGaleazziLFranceschiC. ApoE genotyping in Alzheimer's disease (AD): Multidimensional counseling by the geriatric assessment unit (GAU) to properly address scientific and bioethical issues emerging from molecular gerontology to geriatric practice. Archives of Gerontology & Geriatrics1998;27:49–56.
55.
AnnasGJ. Privacy rules for DNA databanks: Protecting coded ‘future diaries.’JAMA1993;270:2346–50.
56.
BillingsPRKohnMAdeCuervasMBeckwithJAlpenJSNatowiczMR. Discrimination as a consequence of genetic testing. Am J Hum Genet1992;50:476–82.
57.
LaphamEVKozmaCWeissJO. Genetic discrimination: Perspectives of consumers. Science1996;274:621–4.
58.
LemmensTPoupakB. Genetics in life, disability and additional health insurance in Canada: A comparative legal and ethical analysis. In: KnoppersBM, editor, Socio-ethical issues in human genetics. Cowansville (QC): Les Éditions Yvon Blais Inc; 1998. p 107–275.
59.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. Washington (DC): Department of Health, Education and Welfare; 1978.
60.
National Institute of Health, Office of Extramural Research, Office for Protection from Research Risks. Protecting human subjects: International review guidebook. NIH publication 20402–9328. Washington (DC): National Institutes of Health; 1993.
61.
Declaration of Helsinki[Adopted by the World Medical Assembly, Helsinki: 1964. Revised 1975 (Tokyo), 1983 (Vienna), 1989 (Hong Kong)]. In: ReichW, editor. Encyclopedia of Bioethics. Revised, Volume 5. New York: Simon Schuster and Prentice Hall; 1995. p 2765–7.
62.
International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences, 1993.
63.
BeauchampTLChildressJF. Principles of biomedical ethics. 4th ed.New York: Oxford University Press; 1994. p 142–6.
64.
BaskinSAMorrisJAhronheimJCMeirDEMorrisonSE. Barriers to obtaining consent in dementia research: Implications for surrogate decision-making. J Am Geriatr Soc1998;46:287–90.
65.
HighDM. Research with Alzheimer's disease subjects: Informed consent and proxy decision making. J Am Geriatr Soc1992;40:950–7.
66.
SchulmanKALinasBP. Pharmacoeconomics: State of the art. Annual Review of Public Health1997;18:529–48.
67.
ClassenDCPestotnikSLEvansRSLloydJFBurkeJP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA1997;277:301–6.
68.
BootmanJLHarrisonDLCoxE. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med1997;157:2089–96.
69.
MorrisJC. Conflicts of interest: Research and clinical care. Alzheimer Dis Assoc Disord1994;8:49–57.
70.
JarvikGPLarsonEBGoddardKKukullWASchellenbergCDWijsmanEM. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet58:191–200.
